Tirofiban Hydrochloride interactions
Checked as Tirofiban in this data source.
Full monograph for Tirofiban HydrochlorideCheck it against another medicine
Medicines
133 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acalabrutinib | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Allium cepa + Heparin + Allantoin | Major | Synergy | Although glycoprotein IIb/IIIa inhibitors are routinely given with heparin, be cognizant of the increased risk of bleeding due to additive pharmacologic… | 8 sources — open the full entry |
| Alteplase | Major | Synergy | The intended and unintended effects of glycoprotein IIb/IIIa inhibitors and thrombolytic agents are additive, such that there is an increased frequency of… | 4 sources — open the full entry |
| Apixaban | Major | Synergy | Concomitant use of apixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Aspirin + Dipyridamole | Major | Synergy | The combination of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors and other drugs that inhibit platelet aggregation may significantly increase the risk of…2 documented mechanisms | 9 sources — open the full entry |
| Betrixaban | Major | Synergy | Concomitant use of betrixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Cabozantinib | Major | Synergy | Coadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment… | 39 sources — open the full entry |
| Clopidogrel + Aspirin | Major | Synergy | The combination of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors and other drugs that inhibit platelet aggregation may significantly increase the risk of…2 documented mechanisms | 9 sources — open the full entry |
| Clopidogrel Bisulphate | Major | Synergy | The combination of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors and other drugs that inhibit platelet aggregation may significantly increase the risk of… | 5 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Major | Synergy | Drugs that can affect hemostasis such as glycoprotein IIb/IIIa inhibitors, thienopyridine antiplatelet agents, unfractionated and low molecular weight… | 3 sources — open the full entry |
| Dalteparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Dasatinib | Major | Synergy | Coadministration of dasatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with… | 5 sources — open the full entry |
| Deferasirox | Major | Synergy | Coadministration with drugs that have known ulcerogenic or hemorrhagic potential may increase the risk of gastrointestinal bleeding associated with the use of… | 3 sources — open the full entry |
| Dipyridamole | Major | Synergy | The combination of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors and other drugs that inhibit platelet aggregation may significantly increase the risk of… | 5 sources — open the full entry |
| Enoxaparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Eptifibatide | Major | Synergy | Concomitant use of multiple glycoprotein (GP) IIb/IIIa inhibitors may increase the risk of major bleeding events due to additive anticoagulation. | 5 sources — open the full entry |
| Fondaparinux Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Heparin Sodium | Major | Synergy | Although glycoprotein IIb/IIIa inhibitors are routinely given with heparin, be cognizant of the increased risk of bleeding due to additive pharmacologic… | 8 sources — open the full entry |
| Ibrutinib | Major | Synergy | Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 6 sources — open the full entry |
| Ponatinib Hydrochloride | Major | Synergy | Coadministration of ponatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with… | 3 sources — open the full entry |
| Prasugrel Hydrochloride | Major | Synergy | The combination of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors and other drugs that inhibit platelet aggregation may significantly increase the risk of… | 5 sources — open the full entry |
| Ramucirumab | Major | Synergy | Coadministration of ramucirumab and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Ramucirumab… | 2 sources — open the full entry |
| Regorafenib Monohydrate | Major | Synergy | Coadministration of regorafenib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment… | 5 sources — open the full entry |
| Rivaroxaban | Major | Synergy | Concomitant use of rivaroxaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 1 sources — open the full entry |
| Streptokinase | Major | Synergy | The intended and unintended effects of glycoprotein IIb/IIIa inhibitors and thrombolytic agents are additive, such that there is an increased frequency of… | 4 sources — open the full entry |
| Tenecteplase | Major | Synergy | The intended and unintended effects of glycoprotein IIb/IIIa inhibitors and thrombolytic agents are additive, such that there is an increased frequency of… | 4 sources — open the full entry |
| Trastuzumab Emtansine | Major | Synergy | Coadministration of trastuzumab emtansine with anticoagulant or antiplatelet drugs may potentiate the risk of hemorrhagic events associated with these drugs… | 40 sources — open the full entry |
| Warfarin Sodium | Major | Synergy | The risk of bleeding, including major bleeding (intracranial hemorrhage or a decrease in hemoglobin greater than 5 mg/dl) is significantly more likely when… | 39 sources — open the full entry |
| Aspirin | Moderate | Synergy | Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due… | 4 sources — open the full entry |
| Benzoic Acid + Salicylic Acid | Moderate | Synergy | Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due… | 4 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Synergy | Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and… | 20 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Moderate | Synergy | Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due… | 4 sources — open the full entry |
| Bismuth Subsalicylate | Moderate | Synergy | Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due… | 4 sources — open the full entry |
| Bivalirudin | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Cetalkonium Chloride + Choline Salicylate | Moderate | Synergy | Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due… | 4 sources — open the full entry |
| Cilostazol | Moderate | Synergy | Coadministration of cilostazol with other antiplatelet agents may produce additive pharmacodynamic effects resulting in increased inhibition of platelet… | 4 sources — open the full entry |
| Citalopram Hydrobromide | Moderate | Synergy | Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as… | 42 sources — open the full entry |
| Clobetasol Propionate + Salicylic Acid | Moderate | Synergy | Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due… | 4 sources — open the full entry |
| Clomipramine Hydrochloride | Moderate | Synergy | Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as… | 42 sources — open the full entry |
| Coal Tar + Precipitated Sulphur + Salicylic Acid | Moderate | Synergy | Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due… | 4 sources — open the full entry |
| Desvenlafaxine Succinate | Moderate | Synergy | Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as… | 42 sources — open the full entry |
| Dexibuprofen | Moderate | Synergy | The risk of bleeding associated with glycoprotein IIb/IIIa inhibitors is increased in the presence of nonsteroidal anti-inflammatory agents due to additive… | 2 sources — open the full entry |
| Dexketoprofen | Moderate | Synergy | The risk of bleeding associated with glycoprotein IIb/IIIa inhibitors is increased in the presence of nonsteroidal anti-inflammatory agents due to additive… | 2 sources — open the full entry |
| Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil | Moderate | Synergy | The risk of bleeding associated with glycoprotein IIb/IIIa inhibitors is increased in the presence of nonsteroidal anti-inflammatory agents due to additive… | 2 sources — open the full entry |
| Diclofenac Potassium | Moderate | Synergy | The risk of bleeding associated with glycoprotein IIb/IIIa inhibitors is increased in the presence of nonsteroidal anti-inflammatory agents due to additive… | 2 sources — open the full entry |
| Diclofenac Sodium | Moderate | Synergy | The risk of bleeding associated with glycoprotein IIb/IIIa inhibitors is increased in the presence of nonsteroidal anti-inflammatory agents due to additive… | 2 sources — open the full entry |
| Diclofenac Sodium (Ophthalmic) | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Diclofenac Sodium + Lidocaine Hydrochloride | Moderate | Synergy | The risk of bleeding associated with glycoprotein IIb/IIIa inhibitors is increased in the presence of nonsteroidal anti-inflammatory agents due to additive… | 2 sources — open the full entry |
| Diclofenac Sodium + Methyl Salicylate + Linseed Oil + Menthol | Moderate | Synergy | The risk of bleeding associated with glycoprotein IIb/IIIa inhibitors is increased in the presence of nonsteroidal anti-inflammatory agents due to additive… | 2 sources — open the full entry |
| Diclofenac Sodium + Misoprostol | Moderate | Synergy | The risk of bleeding associated with glycoprotein IIb/IIIa inhibitors is increased in the presence of nonsteroidal anti-inflammatory agents due to additive… | 2 sources — open the full entry |
Conditions
Conditions in which Tirofiban Hydrochloride needs care, as documented in this source.
Hemorrhagic Disorders
MajorThe use of gp11b/111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (<100,000/mm3). Thrombocytopenia, serious GI/GU bleeding, hemorrhagic retinopathy, and bleeding at the arterial access have been reported during gp11b/111a platelet inhibitor therapy. Clinical monitoring of hemoglobin and hematocrit (H/H), platelet count, prothrombin time (PT) and activated partial prothrombin time (aPTT) is recommended prior to initiation of, during and following gp11b/111a platelet inhibitor therapy.
9 sources
- Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987): 703-13
- Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ "Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery." Am J Cardiol 74 (1994): 1166-70
- Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP "Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion." Am J Cardiol 78 (1996): 1161
- "Product Information. Aggrastat (tirofiban)." Merck & Co., Inc (2001):
- Adgey AA "An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors." Am Heart J 135 (1998): s43-55
- Kleiman NS "Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis." Am J Cardiol 80 (1997): b29-33
- The IMPACT-II Investigators "Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II." Lancet 349 (1997): 1422-8
- The RESTORE Investigators "Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction..." Circulation 96 (1997): 1445-53
Show all 9 sourcesShow fewer sources
- "Product Information. Integrilin (eptifibatide)." Schering Corporation (2001):
Kidney Diseases
MajorTirofiban is primarily eliminated by the kidney. Approximately 65% of tirofiban is excreted in the urine, largely unchanged. The serum concentration of tirofiban is significantly increased (>50%) in patients with a creatinine clearance <30 mL/min (including hemodialysis patients). Therapy with tirofiban should be administered cautiously and initiated at a reduced dosage in patients with severe renal impairment. Clinical monitoring of renal function and bleeding activity is recommended. Tirofiban is removed by dialysis.
1 source
- "Product Information. Aggrastat (tirofiban)." Merck & Co., Inc (2001):